In summary, we discovered that Necdin null LICs expressing MLL-AF9 are less quiescent than wild-type LICs and Necdin-deficiency enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment. Here, MLLT3 is linked to leukemia.